Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Beth Israel Deaconess Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03550794CT.gov Thiamine as a Renal Protective Agent in Septic Shock | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Kidney Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eskaphen (this asset) | Beth Israel Deaconess Medical Center | P2 | B · 57 |
| Angiotensin Ii | The Cleveland Clinic | P4 | BB |
| Gabapentin | Tanta University | P4 | B |
| Everolimus | MARIO ABBUD FILHO | P4 | B |
| Apsolol | Taipei Veterans General Hospital, Taiwan | P4 | B |
| Normal Human Serum Albumin | Institute of Liver and Biliary Sciences, India | P3 | B |
| Noradrenaline | University of California, Los Angeles | P4 | B |
| Dextran 40 For Injection | Ramathibodi Hospital | P2/3 | B |
| Conestat Alfa | University Hospital, Basel, Switzerland | P2 | B |
+22 more in the Acute Kidney Injury cohort
Other indications for Eskaphen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infectious Disease With Sepsis | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eskaphen in Acute Kidney Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eskaphen-acute-kidney-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →